Uncategorized

Lilly dives into vaccine research with 3 biotech buyouts

Worth close to $4 billion combined, the acquisitions of Curevo, Limmatech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

Read More

Published

on

Worth close to $4 billion combined, the acquisitions of Curevo, Limmatech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version